"Treatment Of Scleroderma" in Patent Application Approval Process (USPTO 20240358692).

A patent application by Andrew Sternlicht discusses the treatment of scleroderma, a disease that causes skin and tissue hardening. The application proposes the use of dual N-type and L-type calcium channel blockers for treating scleroderma symptoms and comorbidities. The invention aims to reduce pain, improve vascular function, and enhance overall quality of life for scleroderma patients. This treatment approach may offer new possibilities for managing this challenging condition. [Extracted from the article]